Does Prozac cause gynaecomastia? Fluoxetine (Prozac), one of the most widely prescribed SSRIs in the UK, lists gynaecomastia as an adverse reaction of 'frequency not known' in its MHRA-regulated Summary of Product Characteristics. Gynaecomastia — the benign enlargement of glandular breast tissue in males — is an uncommon but recognised concern with certain antidepressants. This article explains the proposed hormonal mechanisms, how common the association is, when to seek medical advice, and what your GP or pharmacist can do to help if you notice breast tissue changes whilst taking fluoxetine.

Can Prozac Cause Gynaecomastia?

Fluoxetine (Prozac) lists gynaecomastia as an adverse reaction of 'frequency not known' in its MHRA-regulated SmPC, meaning a causal link is recognised but its precise incidence is unestablished from controlled trial data.

Experiencing these side effects? Our pharmacists can help you navigate them →

Prozac is the brand name for fluoxetine, one of the most widely prescribed selective serotonin reuptake inhibitors (SSRIs) in the UK. It is commonly used to treat depression, obsessive-compulsive disorder (OCD), bulimia nervosa, and panic disorder. Gynaecomastia — the benign enlargement of glandular breast tissue in males — is a recognised, though uncommon, side effect associated with certain medications, including some antidepressants.

It is important to distinguish true gynaecomastia (enlargement of glandular breast tissue) from pseudogynaecomastia, which refers to increased breast size due to adipose (fatty) tissue accumulation and is not a hormonal phenomenon. This distinction matters clinically, as the causes and management differ.

Regarding fluoxetine specifically, the UK Summary of Product Characteristics (SmPC) for fluoxetine — the authoritative prescribing document regulated by the Medicines and Healthcare products Regulatory Agency (MHRA) — lists gynaecomastia as an adverse reaction with a frequency classified as 'not known' (meaning it cannot be estimated from available data, as reports arise from spontaneous post-marketing surveillance rather than controlled trials). Patients and clinicians should be aware that 'frequency not known' does not mean the effect is impossible, but rather that its precise incidence has not been established.

Gynaecomastia has multiple potential causes — including hormonal imbalances, other medications, liver disease, obesity, and natural physiological changes at puberty or with ageing — so attributing it solely to fluoxetine without clinical assessment would be premature. If you notice breast tissue swelling or tenderness whilst taking fluoxetine, this warrants a conversation with your GP rather than immediate discontinuation of the medication, as stopping antidepressants abruptly carries its own risks.

Sources: MHRA/EMC fluoxetine SmPC; NHS: Gynaecomastia; NICE CKS: Gynaecomastia.

How Fluoxetine May Affect Hormone Levels

Fluoxetine may raise prolactin levels by increasing serotonergic activity, which can suppress testosterone and potentially stimulate breast tissue growth, though this mechanism is based largely on case reports rather than robust clinical trial evidence.

Understanding why fluoxetine might contribute to gynaecomastia requires a brief look at its pharmacology. Fluoxetine works primarily by blocking the reuptake of serotonin in the brain, increasing serotonergic activity at synapses. Serotonin does not act in isolation — it interacts with several other hormonal systems in the body.

Elevated serotonin levels can stimulate the release of prolactin from the pituitary gland, a phenomenon known as hyperprolactinaemia. Prolactin is a hormone primarily associated with lactation, but in males, raised prolactin levels can suppress testosterone production and, in some cases, stimulate breast tissue growth. This hormonal interplay is considered a plausible mechanism by which SSRIs, including fluoxetine, could theoretically contribute to gynaecomastia, though it is based largely on case reports and small series rather than robust clinical trial data.

Fluoxetine and its active metabolite norfluoxetine are potent inhibitors of the cytochrome P450 enzyme CYP2D6, and have weak inhibitory effects on CYP3A4. Whilst CYP enzymes are involved in the metabolism of various substances including some sex hormones, there is no well-established clinical evidence that fluoxetine's enzyme inhibition meaningfully disrupts the oestrogen–testosterone balance in most patients. This proposed mechanism remains speculative and should not be overstated.

Individual susceptibility, concurrent medications, and underlying health conditions all play a role in determining whether hormonal side effects manifest. Clinically significant hormonal disruption attributable to fluoxetine alone is considered uncommon.

Sources: BNF fluoxetine monograph (CYP interactions); MHRA/EMC fluoxetine SmPC; published reviews of SSRI-associated hyperprolactinaemia.

How Common Is Gynaecomastia With Antidepressants?

Gynaecomastia directly caused by antidepressants is considered rare; it is more frequently associated with antipsychotics, spironolactone, and anabolic steroids than with SSRIs such as fluoxetine.

Gynaecomastia as a direct consequence of antidepressant use is considered rare. Across the broader class of SSRIs and serotonin-norepinephrine reuptake inhibitors (SNRIs), case reports exist for several agents, but large-scale epidemiological data specifically linking fluoxetine to gynaecomastia remain limited.

The condition is more frequently associated with other drug classes, including:

• Antipsychotics (e.g., haloperidol, risperidone), which more potently raise prolactin levels

• Spironolactone, an aldosterone antagonist with anti-androgenic properties

• Anabolic steroids and exogenous testosterone therapy

• H2-receptor antagonists such as cimetidine, which have a well-documented association with gynaecomastia

• Certain cardiovascular medications, including verapamil and digoxin

Note that the association between proton pump inhibitors (PPIs) and gynaecomastia is inconsistent and less well established in the literature; H2-receptor antagonists such as cimetidine carry a clearer evidence base.

It is also important to recognise common non-drug causes of gynaecomastia, including physiological changes at puberty and with ageing, obesity-related pseudogynaecomastia, hypogonadism, hyperthyroidism, liver disease, and testicular or adrenal tumours. Depression itself, and associated lifestyle factors — including weight changes, alcohol use, and reduced physical activity — can independently influence hormone levels and contribute to breast tissue changes. This makes establishing a direct causal relationship between fluoxetine and gynaecomastia particularly challenging in real-world clinical settings.

In clinical practice, when a patient taking fluoxetine presents with gynaecomastia, clinicians are advised to consider the full medication history and systematically exclude other causes before attributing the symptom to the antidepressant.

Sources: NICE CKS: Gynaecomastia; BNF (drug causes of gynaecomastia); MHRA/EMC fluoxetine SmPC.

When to Speak to Your GP or Pharmacist

Seek prompt medical advice if you notice breast swelling, tenderness, nipple discharge, or any new breast lump whilst taking fluoxetine; do not stop the medication without GP guidance due to the risk of discontinuation syndrome.

If you are taking fluoxetine and notice any of the following, it is advisable to seek prompt medical advice:

• Swelling, tenderness, or enlargement of breast tissue

• Nipple discharge (galactorrhoea), which may suggest elevated prolactin

• Persistent breast pain that does not resolve within a few weeks

• Any new breast lump, regardless of medication use, which should always be assessed to exclude malignancy

• Nipple retraction, skin changes, or other features that may suggest a more serious underlying cause

Urgent referral: In line with NICE NG12 (Suspected Cancer: Recognition and Referral), any unexplained breast lump, nipple retraction, skin changes, or unilateral nipple discharge in a male patient should prompt consideration of an urgent 2-week-wait referral to exclude breast malignancy. Do not delay seeking advice if you are concerned.

Your GP may arrange blood tests to help identify an underlying hormonal cause. These may include prolactin, testosterone, oestradiol, thyroid function (TSH), human chorionic gonadotrophin (hCG), luteinising hormone (LH), follicle-stimulating hormone (FSH), liver function, and renal function. A testicular examination and, where indicated, testicular ultrasound may also be recommended to exclude a testicular cause. If prolactin is markedly elevated and accompanied by symptoms such as persistent headache or visual disturbance, urgent endocrine assessment is warranted to exclude a pituitary cause.

In some cases, a referral to an endocrinologist or a breast clinic may be appropriate, particularly if symptoms are persistent or worsening. It is worth noting that early, tender gynaecomastia may regress once the underlying cause is addressed, whereas long-standing changes are generally less reversible.

It is essential that you do not stop taking fluoxetine without medical guidance. Abrupt discontinuation of SSRIs can lead to discontinuation syndrome — characterised by dizziness, nausea, flu-like symptoms, and mood disturbance — and may also risk a relapse of the underlying mental health condition being treated. Your GP or pharmacist can advise on whether a dose adjustment, gradual tapering, or switch to an alternative medication is appropriate based on your individual circumstances.

Your community pharmacist is also an accessible first point of contact for medication-related concerns and can help you decide whether an urgent GP appointment is needed.

Sources: NICE NG12: Suspected Cancer Recognition and Referral; NICE CKS: Gynaecomastia; NHS: Gynaecomastia.

Alternative Antidepressants and Hormonal Side Effects

If gynaecomastia is confirmed and linked to fluoxetine, your doctor may consider switching to an alternative such as mirtazapine, though no antidepressant is entirely free from hormonal side effects and switching must follow NICE NG222 guidance.

If gynaecomastia is confirmed and thought to be related to fluoxetine, your doctor may consider switching to an alternative antidepressant. It is important to understand, however, that no antidepressant is entirely free from the potential to influence hormone levels, and individual responses vary considerably. Case reports of gynaecomastia exist across multiple SSRI agents, including citalopram and escitalopram, and there is insufficient robust evidence to rank SSRIs reliably by their propensity to raise prolactin or cause gynaecomastia.

Mirtazapine, a noradrenergic and specific serotonergic antidepressant (NaSSA), works via a different mechanism and may be less likely to elevate prolactin, though it carries its own side-effect profile, including weight gain and sedation.

Not sure if this is normal? Chat with one of our pharmacists →

Venlafaxine and duloxetine (SNRIs) may also be considered, though they too can influence prolactin to varying degrees, and evidence is largely case-based.

Regarding bupropion: in the UK, bupropion is licensed only for smoking cessation (as Zyban) and is not licensed for the treatment of depression. Any use for depression would be off-label and would require specialist oversight. Clinicians and patients should be aware of this distinction; the US brand name Wellbutrin is not available or licensed in the UK.

A practical consideration when switching from fluoxetine is its unusually long half-life (and that of its active metabolite norfluoxetine), which means a washout period or modified cross-tapering schedule may be required. The BNF and NICE NG222 provide specific guidance on switching antidepressants safely.

NICE guidelines on depression (NG222) recommend a shared decision-making approach when selecting or switching antidepressants, taking into account the patient's symptom profile, previous treatment response, tolerability, and personal preferences. Any switch should be managed carefully, with appropriate cross-tapering where indicated, under the supervision of a GP or psychiatrist.

Sources: NICE NG222: Depression in Adults; BNF fluoxetine and antidepressant switching guidance; MHRA/EMC SmPCs for relevant agents.

MHRA Guidance and Reporting Medication Side Effects

The MHRA lists gynaecomastia in fluoxetine's SmPC and operates the Yellow Card scheme at yellowcard.mhra.gov.uk, where patients and clinicians can report suspected adverse drug reactions to support ongoing pharmacovigilance.

The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK body responsible for regulating medicines and medical devices, ensuring they meet acceptable standards of safety, quality, and efficacy. Fluoxetine is a licensed medicine in the UK, and its Summary of Product Characteristics (SmPC) — the official prescribing document — lists gynaecomastia as an adverse reaction with a frequency of 'not known'. The SmPC is publicly available via the MHRA/EMC website and is reviewed and updated as new safety data emerge.

The MHRA operates the Yellow Card scheme, which is the UK's pharmacovigilance system for reporting suspected adverse drug reactions. Both healthcare professionals and patients can submit a Yellow Card report online at yellowcard.mhra.gov.uk or via the Yellow Card app. Reporting side effects — even if you are not certain the medication is responsible — is valuable, as it contributes to the ongoing monitoring of drug safety in real-world populations and can prompt regulatory review if a pattern emerges.

For patients seeking further information, the NHS website and the patient information leaflet included with your medication packaging provide accessible summaries of known side effects and what to do if they occur. The European Medicines Agency (EMA) publishes European Public Assessment Reports (EPARs) for medicines authorised at EU level; whilst the EMA no longer regulates UK medicines following the UK's departure from the European Union, its published safety summaries may provide useful supplementary context. The MHRA remains the sole regulatory authority for medicines in the UK.

If you believe you have experienced a side effect from fluoxetine or any other medicine, reporting it through the Yellow Card scheme is encouraged and helps protect other patients. Always discuss any concerns about your medication with a qualified healthcare professional before making changes to your treatment.

Sources: MHRA/EMC fluoxetine SmPC; MHRA Yellow Card scheme (yellowcard.mhra.gov.uk); NHS: Gynaecomastia.

Frequently Asked Questions